ClinicalTrials.gg

Program

sonidegib

Also written as “LDE225”, “Sonidegib Phosphate Capsules” and “LDE225+gemcitabine”.

Its studies are mostly in Medulloblastoma · Carcinoma, Basal Cell · Basal Cell Nevus Syndrome · Breast Neoplasms · Pancreatic Neoplasms, led by 2 companies.

Furthest: phase 4, since Dec 15, 200916 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis150 open or runningphase 2since Dec 15, 2009Apr 9, 2009none ahead
Jemincare10 open or runningphase 4since Mar 12, 2025Mar 12, 2025none ahead

Also a collaborator on its studies: Sun Pharmaceutical Industries and zhejiang-hangyu-pharmaceutical-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Apr 9, 2009.

  1. Dec 15, 2009Phase 2 study in Carcinoma, Basal CellNovartis · NCT01033019 · 25 enrolled · Australia, Austria
  2. May 12, 2010Phase 2 study in MedulloblastomaNovartis · NCT01125800 · 76 enrolled · United States, Australia, Canada and more
  3. Sep 21, 2010Phase 1 study in MedulloblastomaNovartis · NCT01208831 · 45 enrolled · Hong Kong, Japan, Taiwan
  4. Mar 30, 2011Phase 2 study in Carcinoma, Basal CellNovartis · NCT01327053 · 230 enrolled · United States, Australia, Belgium and more
  5. May 6, 2011Phase 2 study in Carcinoma, Basal CellNovartis · NCT01350115 · 10 enrolled · Austria, Belgium, Canada and more
  6. Oct 14, 2011Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT01456676 · 11 enrolled · Canada, France, Germany and more
  7. Dec 5, 2011Phase 1 study in Pancreatic NeoplasmsNovartis · NCT01487785 · 18 enrolled · United States, Spain, United Kingdom
  8. Apr 10, 2012Phase 1 study in Breast NeoplasmsNovartis · NCT01576666 · 120 enrolled · United States, Australia, Belgium and more
  9. Oct 11, 2012Phase 2 study in MedulloblastomaNovartis · NCT01708174 · 22 enrolled · United States, Australia, Brazil and more
  10. Jan 8, 20132 phase 1 studiesNovartis · NCT01764776, NCT01769768
  11. Feb 6, 2013Phase 2 study in Primary MyelofibrosisNovartis · NCT01787552 · 50 enrolled · Australia, Belgium, Canada and more
  12. Mar 25, 2013Phase 2 study in Leukemia, Myeloid, AcuteNovartis · NCT01826214 · 70 enrolled · United States, Australia, Austria and more
  13. Dec 1, 2013Phase 2 study in Basal Cell Nevus SyndromeNovartis · NCT02002689 · 10 enrolled · United States
  14. Mar 12, 2025Jemincare's first study: phase 4 study in CarcinomaNew to JemincareJemincare · NCT06880848 · 160 enrolled · China

TargetBeta

SMO →read by rule
“Smoothened homolog inhibitor”ChEMBL 37, by rule

Other programs on SMO

ProgramCompanyFurthest phaseStudies
taladegibruleEli Lillyphase 211

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06880848Carcinoma · China4CompletedJemincareAug 26, 2025160
NCT02002689Basal Cell Nevus Syndrome · United States2TerminatedNovartisMar 201510
NCT01826214Leukemia, Myeloid, Acute · United States, Australia, Austria and more2CompletedNovartisMay 201570
NCT01787552Primary Myelofibrosis · Australia, Belgium, Canada and more2CompletedNovartisApr 10, 201850
NCT01769768Advanced Solid Tumor · United States1CompletedNovartisAug 2016114
NCT01764776Normal Hepatic Function · United States, Belgium, Bulgaria and more1CompletedNovartisMar 201533
NCT01708174Medulloblastoma · United States, Australia, Brazil and more2CompletedNovartisOct 5, 201622
NCT01576666Breast Neoplasms · United States, Australia, Belgium and more1CompletedNovartisApr 2015120
NCT01487785Pancreatic Neoplasms · United States, Spain, United Kingdom1CompletedNovartisJul 201418
NCT01456676Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Canada, France, Germany and more1CompletedNovartisFeb 201411
NCT01350115Carcinoma, Basal Cell · Austria, Belgium, Canada and more2CompletedNovartisOct 201210
NCT01327053Carcinoma, Basal Cell · United States, Australia, Belgium and more2CompletedNovartisJun 28, 2013230
NCT01208831Medulloblastoma · Hong Kong, Japan, Taiwan1CompletedNovartisOct 201345
NCT01125800Medulloblastoma · United States, Australia, Canada and more2CompletedNovartisOct 201476
NCT01033019Carcinoma, Basal Cell · Australia, Austria2TerminatedNovartisFeb 201125
NCT00880308Medulloblastoma · United States, Spain, Switzerland and more1CompletedNovartisJul 2013103

How it is read

Names in the registry

  • “LDE225”, 12 entries
  • “Sonidegib Phosphate Capsules”, 1 entry
  • “LDE225+gemcitabine”, 1 entry
  • “Nilotinib + LDE225”, 1 entry
  • “LDE225 0.75%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.